跳至主要内容
临床试验/JPRN-UMIN000000933
JPRN-UMIN000000933已完成1 期

Phase I clinical trial of WT1 peptide-based vaccine for the HLA-A*0201 positive patients with malignant tumors. - Phase I clinical trial of WT1 peptide-based vaccine for the HLA-A*0201 positive patients with malignant tumors.

Department of Cancer immunotherapy, Osaka University Medical School0 个研究点目标入组 10 人开始时间: 2008年1月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16years-old 至 79years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. There is deep-seated active infection. 2,3 There are severe complications including malignant hypertention, cardiac failure, liver cirrhosis, severe DM, severe lung fiblosis, active interstitial pneumonitis.Patients who have complications that are considered inappropriate for the trial. 4. Dependent on total parenteral nutrition(TPN) 5. There is expanded liver metastasis. 6. There are other malignancies. 7. There are hematopoietic stem cell disorders such as myelodisplastic syndorome(MDS) and myeloproliferative disorders (MPD). 8. Post allogeneic hematopoietic stem cell transplantation 9. Pregnant or lactating woman 10. There is severe psychiatric disorder. 11. Responsible doctors judged the patient inappropriate for the trial

研究者

发起方
Department of Cancer immunotherapy, Osaka University Medical School

相似试验